Reported 2 days ago
Despite a prior agreement with Eli Lilly to cease sales of compounded GLP-1 weight-loss medications, telehealth partners like Ro and Noom continue to offer these products, following a recent FDA end to the drug shortage. Eli Lilly warns that ongoing sales pose risks to patient safety and legal consequences. Some compounding pharmacies exploit perceived regulatory loopholes to justify their actions by calling their products 'personalized'. Meanwhile, both Lilly and competitor Novo Nordisk are engaged in legal actions against these sales practices.
Source: YAHOO